Recent developments: Criteria influencing the clinical uptake of pharmacogenomic strategies

British Medical Journal

Volumn 328, Issue 7454, 2004, Pages 1482-1486

  Shah, Jai ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CLOZAPINE; CODEINE; INTERFERON; MERCAPTOPURINE; RIBAVIRIN; TRASTUZUMAB; DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; CLINICAL TRIAL; GENOMICS; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS; DECISION MAKING; DRUG INTERACTION; GENETIC SCREENING; GENETICS AND REPRODUCTION; GENOME; PHARMACEUTICS; PHARMACOGENETICS; REPRODUCIBILITY;

GENETICS AND REPRODUCTION;

DECISION MAKING; DRUG INTERACTIONS; GENETIC SCREENING; GENOME, HUMAN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 3042662029     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ 2001;322:1052-6.
2. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al. Genetic test evaluation: Information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156:311-8.
3. Birmingham K. Experts predict bleak post-genomic era for drug R&D. Nature Med 2001;7:262.
4. Norton RM. Clinical pharmacogenetics: Applications in pharmaceutical R&D. Drug Discov Today 2001;6:180-5.
5. Owens J, Ramster B, Lawrence RN. Impact of SNP genotyping could save millions by 2010. Drug Discov Today 2001;6:450.
6. Ward SJ. Impact of genomics in drug discovery. BioTechniques (Euro Edition) 2001:64-9.
7. Phillips KA, Veenstra DL, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003;4:231-9.
8. Bristol L. A regulatory protocol for pharmacogenomics services. Pharmacogenomics J 2002;2:83-6.
9. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature Rev Drug Discov 2002;1:300-8.
10. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nature Rev Genet 2001;2:228-31.
11. Robertson JA, Brody B, Buchanan A, Kahn J, McPherson E. Pharmacogenetic challenges for the health care system. Health Aff 2002;21:155-67.
12. Shah J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nature Biotechnol 2003;21:747-53.
13. Melzer D, Raven A, Detmer DE, Ling T, Zimmern RL. My very own medicine: What must I know? Cambridge: Department of Public Health and Primary Care, University of Cambridge, 2003.
14. Lindpaintner K. The importance of being modest: Reflections on the pharmacogenetics of abacavir. Pharmacogenomics 2002;3:835-8.
15. Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: A decision analysis. Hepatology 2002;36:177-85.
16. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001;286:2270-9.
17. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-11.
18. Tollman P, Guy P, Altshuler J, Flanagan A, Steiner M. A revolution in R&D: how genomics and genetics are transforming the biopharmaceutical industry. Boston, MA: Boston Consulting Group, 2001.
19. National Institute for Clinical Excellence. Technology Appraisal Guidance No.34. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. London: National Institute for Clinical Excellence, 2002.
20. Wolf CR, Smith G. Pharmacogenetics. Br Med Bull 1999;55:366-86.
21. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenetics. AAPS PharmSci 2000;2:article 29.
22. Marshall E. Preventing toxicity with a gene test. Science 2003;302:588-90.
23. Branca M. FDA fosters pharmacogenomics, Bio IT World 2002. www.bio-itworld.com/archive/061202/horizons_lesko.html (accessed 18 May 2004).
24. Van Aken J, Schmedders M, Feuerstein G, Kollek R. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003;3:149-55.
25. Krynetski E, Evans W. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003;22:7403-13.
26. Roche Diagnostics. Roche diagnostics launches the AmpliChip CYP450 in the US, the world's first pharmacogenomic microarray for clinical applications: Roche Diagnostics, 2003. www.roche.com/med-cor-2003-06-25 (accessed 7 Jun 2004).